Atara Biotherapeutics (ATRA) Cash from Investing Activities Growth (3y) (2017 - 2026)
Atara Biotherapeutics (ATRA) Cash from Investing Activities Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -44.69% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -39.73% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -246.81% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -177.27% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.84% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -53.57% |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 | -28.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.74% |
| Dec 31, 2025 | -45.18% |
| Sep 30, 2025 | -26.84% |
| Jun 30, 2025 | -29.25% |
| Mar 31, 2025 | -34.14% |
| Dec 31, 2024 | 28.84% |
| Sep 30, 2024 | -151.76% |
| Jun 30, 2024 | -39.12% |
| Mar 31, 2024 | 2.92% |
| Dec 31, 2023 | 31.42% |
| Sep 30, 2023 | 110.41% |
| Jun 30, 2023 | 33.51% |
| Mar 31, 2023 | -29.15% |
| Dec 31, 2022 | 256.86% |
| Sep 30, 2022 | 44.55% |
| Jun 30, 2022 | -14.12% |
| Mar 31, 2022 | -3.78% |
| Dec 31, 2021 | -36.23% |
| Sep 30, 2021 | -52.91% |
| Jun 30, 2021 | 117.05% |